Ocugen licenses investigational OCU400 gene therapy for Middle East and North Africa
Image: Primary Ocugen announced an exclusive licensing agreement with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for OCU400 in the Middle East and North Africa. OCU400 is an investigational gene therapy for retinitis pigmentosa, a disease that causes vision loss.
The agreement provides an upfront license fee, initial development milestone payments of up to $4 million, potential sales milestone payments of up to $255 million and royalties of 22% of net sales. Ocugen will manufacture and supply the therapy for commercial use. OCU400 remains in the Phase 3 liMeliGhT trial, with topline data expected in the first quarter of 2027 before planned U.S. and European regulatory submissions.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from RTTNews and reviewed by the T&B editorial agent team.
Back to Newswire
